Zobrazeno 1 - 10 of 165 pro vyhledávání: '"G Tsaban"'
1
Lipid-lowering therapy after acute coronary syndromes in Europe: can we do better?
Autor: G Tsaban, R Vidal Perez, K K Krychtiuk, I Ahrens, S Halvorsen, C Hassager, K Huber, F Schiele, A Sionis, M J Claeys
Publikováno v: European Heart Journal: Acute Cardiovascular Care. 12
Funding Acknowledgements Type of funding sources: None. Background Recent guidelines on acute coronary syndromes (ACS) recommend initiating lipid-lowering therapy (LLT) as soon as possible in order to obtain >50% LDL-cholesterol reduction with a low-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::050e8755a14732a5342bfcc1113b09a3
https://doi.org/10.1093/ehjacc/zuad036.172
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Amiodarone and lung toxicity in a real-life contemporary population
Autor: G Tsaban, M Gordon, Y Omari, L Kezerle, H Alnsasra, K Buturlin, S Bareza, A Wagshal, Y Konnstantino, V Novack, M Haim
Publikováno v: European Heart Journal. 43
Background Amiodarone-induced lung toxicity (ALT) is severe and potentially fatal. Most data on ALT are derived from previous decades when amiodarone was administrated chronically in higher doses, while currently, low-dose amiodarone 200 mg is routin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e23c7c61342db751f97bfc2721c7f252
https://doi.org/10.1093/eurheartj/ehac544.436
Zobrazit plný text záznamu
5
Sex differences among patients with tachyarrhythmias and bradyarrhythmias following acute myocardial infarction
Autor: H Alnsasra, G Tsaban, J Cooper, M Haim
Publikováno v: European Heart Journal. 43
Background Acute myocardial infarction (AMI) is commonly complicated by ventricular, supraventricular tachycardias and high-grade atrioventricular block (HAVB) which may result in increased morbidity and mortality. Purpose To evaluate the sex differe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e33d09e6a7e786aeefe632163ea8c25e
https://doi.org/10.1093/eurheartj/ehac544.660
Zobrazit plný text záznamu
6
The prognostic impact of coronary anatomy in myocardial infarction with nonobstructive coronary artery disease: a seven-year longitudinal follow-up
Autor: G Tsaban, O Barret, I Peles, Y Abramowitz, H Shmueli, C Cafri, D Zahger, E Koifman
Publikováno v: European Heart Journal. 43
Background Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a common condition associated with major adverse events (MAE) that may occur presence of normal or nonobstructive coronary artery anatomy (NCAA and NOCAA, respectively
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d791a80577dc8e8478aaca82381d521
https://doi.org/10.1093/eurheartj/ehac544.1451
Zobrazit plný text záznamu
7
Prognostic factors of patients with myocardial infarction with nonobstructive coronary artery disease: a seven-year longitudinal follow-up
Autor: G Tsaban, O Barret, I Peles, Y Abramowitz, H Shmueli, C Cafri, D Zahger, E Koifman
Publikováno v: European Heart Journal. 43
Background Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a common condition associated with major adverse events (MAE). Unlike obstructive coronary artery disease (OCAD), data regarding the prognosis of MINOCA are scarce. Me
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0df9ecc3056339cfef5d6a3aa7bb91cf
https://doi.org/10.1093/eurheartj/ehac544.1452
Zobrazit plný text záznamu
8
Chronic amiodarone therapy and mortality among atrial fibrillation patients; insights from a real-life contemporary population
Autor: G Tsaban, M Gordon, Y Omari, L Kezerle, H Alnsasra, K Buturlin, S Bareza, A Wagshal, V Novack, Y Konstantino, M Haim
Publikováno v: European Heart Journal. 43
Background Although associated with potentially serious side effects, amiodarone is the most effective pharmacotherapy to achieve rhythm control among patients with atrial fibrillation (AF). Recent clinical trials advocate early rhythm control in AF.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb2f4dfe54ffed23d4ca321fa88c0f22
https://doi.org/10.1093/eurheartj/ehac544.438
Zobrazit plný text záznamu
9
Cardiac dysrhythmias among coronavirus-19 recovered symptomatic patients
Autor: D Shamia, G Tsaban, L Baham, Y Raviv, M Haim
Publikováno v: European Heart Journal. 43
Background The coronavirus (COVID-19) pandemic, which affected millions of people worldwide, is associated with a chronic fatigue sequela, also known as long-COVID. While various adverse effects of COVID-19 on the cardiovascular system were reported,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba7883bab0eafc15485924b2eb4bcc13
https://doi.org/10.1093/eurheartj/ehac544.400
Zobrazit plný text záznamu
10
Amiodarone therapy and risk of primary lung cancer; insights from a real-life contemporary population study
Autor: G Tsaban, M Gordon, Y Omari, L Kezerle, H Alnsasra, K Buturlin, S Bareza, A Wagshal, V Novack, Y Konnstantino, M Haim
Publikováno v: European Heart Journal. 43
Background Amiodarone is the most effective antiarrhythmic therapy to maintain sinus rhythm in atrial fibrillation (AF) patients. There is a controversy regarding the association of amiodarone therapy with an increased risk of lung cancer. We aimed t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f6b4a4870cbff70af6efdf723505ac1
https://doi.org/10.1093/eurheartj/ehac544.437
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje